nodes	percent_of_prediction	percent_of_DWPC	metapath
Propranolol—CYP3A4—bone cancer	0.692	1	CbGaD
Propranolol—SLC22A2—Cisplatin—bone cancer	0.0731	0.529	CbGbCtD
Propranolol—ABCB1—Cisplatin—bone cancer	0.0195	0.141	CbGbCtD
Propranolol—ABCB1—Doxorubicin—bone cancer	0.013	0.0943	CbGbCtD
Propranolol—ABCB1—Methotrexate—bone cancer	0.0126	0.0913	CbGbCtD
Propranolol—CYP2D6—Doxorubicin—bone cancer	0.0123	0.0888	CbGbCtD
Propranolol—HTR1B—dura mater—bone cancer	0.0082	0.408	CbGeAlD
Propranolol—CYP3A4—Doxorubicin—bone cancer	0.00781	0.0565	CbGbCtD
Propranolol—HTR1B—trigeminal nerve—bone cancer	0.00353	0.175	CbGeAlD
Propranolol—ORM1—vertebral column—bone cancer	0.00263	0.131	CbGeAlD
Propranolol—HTR1B—cranial nerve—bone cancer	0.00251	0.125	CbGeAlD
Propranolol—Arterial thrombosis—Methotrexate—bone cancer	0.00229	0.0337	CcSEcCtD
Propranolol—Infection—Carboplatin—bone cancer	0.00136	0.02	CcSEcCtD
Propranolol—ADRB3—connective tissue—bone cancer	0.00119	0.0593	CbGeAlD
Propranolol—Pain—Carboplatin—bone cancer	0.00117	0.0172	CcSEcCtD
Propranolol—Hyperkalaemia—Cisplatin—bone cancer	0.00111	0.0163	CcSEcCtD
Propranolol—Body temperature increased—Carboplatin—bone cancer	0.00108	0.0159	CcSEcCtD
Propranolol—Ranolazine—CYP3A4—bone cancer	0.000929	0.188	CrCbGaD
Propranolol—Terbinafine—CYP3A4—bone cancer	0.000929	0.188	CrCbGaD
Propranolol—Cardiac failure congestive—Cisplatin—bone cancer	0.000901	0.0133	CcSEcCtD
Propranolol—Cinacalcet—CYP3A4—bone cancer	0.000895	0.181	CrCbGaD
Propranolol—Amnesia—Cisplatin—bone cancer	0.00087	0.0128	CcSEcCtD
Propranolol—Bisoprolol—CYP3A4—bone cancer	0.000864	0.174	CrCbGaD
Propranolol—Anaphylactoid reaction—Cisplatin—bone cancer	0.000844	0.0124	CcSEcCtD
Propranolol—Skin ulcer—Methotrexate—bone cancer	0.000793	0.0117	CcSEcCtD
Propranolol—Irritability—Cisplatin—bone cancer	0.00078	0.0115	CcSEcCtD
Propranolol—Rash erythematous—Epirubicin—bone cancer	0.000755	0.0111	CcSEcCtD
Propranolol—Skin ulcer—Epirubicin—bone cancer	0.000742	0.0109	CcSEcCtD
Propranolol—Rash erythematous—Doxorubicin—bone cancer	0.000698	0.0103	CcSEcCtD
Propranolol—Skin ulcer—Doxorubicin—bone cancer	0.000687	0.0101	CcSEcCtD
Propranolol—Atrioventricular block—Epirubicin—bone cancer	0.000596	0.00877	CcSEcCtD
Propranolol—Bradycardia—Cisplatin—bone cancer	0.000575	0.00847	CcSEcCtD
Propranolol—Abnormal dreams—Epirubicin—bone cancer	0.000571	0.00841	CcSEcCtD
Propranolol—Hyperkalaemia—Epirubicin—bone cancer	0.000568	0.00836	CcSEcCtD
Propranolol—Atrioventricular block—Doxorubicin—bone cancer	0.000551	0.00811	CcSEcCtD
Propranolol—Visual impairment—Cisplatin—bone cancer	0.000545	0.00802	CcSEcCtD
Propranolol—Dry eye—Epirubicin—bone cancer	0.000534	0.00786	CcSEcCtD
Propranolol—Abnormal dreams—Doxorubicin—bone cancer	0.000529	0.00778	CcSEcCtD
Propranolol—Hyperkalaemia—Doxorubicin—bone cancer	0.000525	0.00773	CcSEcCtD
Propranolol—Cardiac disorder—Cisplatin—bone cancer	0.000525	0.00772	CcSEcCtD
Propranolol—Propafenone—CYP3A4—bone cancer	0.000509	0.103	CrCbGaD
Propranolol—Alopecia—Cisplatin—bone cancer	0.000499	0.00735	CcSEcCtD
Propranolol—Dry eye—Doxorubicin—bone cancer	0.000494	0.00727	CcSEcCtD
Propranolol—Erythema—Cisplatin—bone cancer	0.000492	0.00724	CcSEcCtD
Propranolol—ADRB1—connective tissue—bone cancer	0.000488	0.0242	CbGeAlD
Propranolol—Dermatitis exfoliative—Methotrexate—bone cancer	0.000475	0.00699	CcSEcCtD
Propranolol—Visual disturbance—Methotrexate—bone cancer	0.000473	0.00696	CcSEcCtD
Propranolol—Vascular purpura—Epirubicin—bone cancer	0.000469	0.0069	CcSEcCtD
Propranolol—Anaphylactoid reaction—Methotrexate—bone cancer	0.000463	0.00682	CcSEcCtD
Propranolol—Cardiac failure congestive—Epirubicin—bone cancer	0.000463	0.00681	CcSEcCtD
Propranolol—Carvedilol—CYP3A4—bone cancer	0.000458	0.0926	CrCbGaD
Propranolol—Lethargy—Methotrexate—bone cancer	0.000458	0.00673	CcSEcCtD
Propranolol—Dermatitis exfoliative—Epirubicin—bone cancer	0.000445	0.00654	CcSEcCtD
Propranolol—Purpura—Epirubicin—bone cancer	0.000435	0.00641	CcSEcCtD
Propranolol—Vascular purpura—Doxorubicin—bone cancer	0.000434	0.00639	CcSEcCtD
Propranolol—Anaphylactoid reaction—Epirubicin—bone cancer	0.000434	0.00638	CcSEcCtD
Propranolol—Hypoglycaemia—Epirubicin—bone cancer	0.00043	0.00633	CcSEcCtD
Propranolol—Lethargy—Epirubicin—bone cancer	0.000428	0.0063	CcSEcCtD
Propranolol—Cardiac failure congestive—Doxorubicin—bone cancer	0.000428	0.0063	CcSEcCtD
Propranolol—Irritability—Methotrexate—bone cancer	0.000428	0.0063	CcSEcCtD
Propranolol—Convulsion—Cisplatin—bone cancer	0.000426	0.00627	CcSEcCtD
Propranolol—Mood swings—Methotrexate—bone cancer	0.000425	0.00625	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—bone cancer	0.000416	0.00612	CcSEcCtD
Propranolol—Affect lability—Epirubicin—bone cancer	0.000413	0.00608	CcSEcCtD
Propranolol—Dermatitis exfoliative—Doxorubicin—bone cancer	0.000411	0.00605	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Methotrexate—bone cancer	0.000404	0.00594	CcSEcCtD
Propranolol—Purpura—Doxorubicin—bone cancer	0.000403	0.00593	CcSEcCtD
Propranolol—Anaphylactic shock—Cisplatin—bone cancer	0.000402	0.00591	CcSEcCtD
Propranolol—Anaphylactoid reaction—Doxorubicin—bone cancer	0.000401	0.0059	CcSEcCtD
Propranolol—Cardiac arrest—Epirubicin—bone cancer	0.000399	0.00587	CcSEcCtD
Propranolol—Infection—Cisplatin—bone cancer	0.000399	0.00587	CcSEcCtD
Propranolol—Hypoglycaemia—Doxorubicin—bone cancer	0.000398	0.00585	CcSEcCtD
Propranolol—Mood swings—Epirubicin—bone cancer	0.000397	0.00585	CcSEcCtD
Propranolol—Lethargy—Doxorubicin—bone cancer	0.000396	0.00583	CcSEcCtD
Propranolol—Nervous system disorder—Cisplatin—bone cancer	0.000394	0.0058	CcSEcCtD
Propranolol—Skin disorder—Cisplatin—bone cancer	0.00039	0.00574	CcSEcCtD
Propranolol—Affect lability—Doxorubicin—bone cancer	0.000382	0.00562	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Epirubicin—bone cancer	0.000378	0.00556	CcSEcCtD
Propranolol—Cardiac arrest—Doxorubicin—bone cancer	0.000369	0.00543	CcSEcCtD
Propranolol—ORM1—bone marrow—bone cancer	0.000368	0.0183	CbGeAlD
Propranolol—Mood swings—Doxorubicin—bone cancer	0.000368	0.00541	CcSEcCtD
Propranolol—Atomoxetine—CYP3A4—bone cancer	0.000367	0.0741	CrCbGaD
Propranolol—ORM1—spinal cord—bone cancer	0.000367	0.0182	CbGeAlD
Propranolol—Neutropenia—Methotrexate—bone cancer	0.000362	0.00533	CcSEcCtD
Propranolol—Paraesthesia—Cisplatin—bone cancer	0.000361	0.00531	CcSEcCtD
Propranolol—Dyspnoea—Cisplatin—bone cancer	0.000358	0.00527	CcSEcCtD
Propranolol—Erectile dysfunction—Methotrexate—bone cancer	0.000357	0.00525	CcSEcCtD
Propranolol—Toxic epidermal necrolysis—Doxorubicin—bone cancer	0.00035	0.00514	CcSEcCtD
Propranolol—Decreased appetite—Cisplatin—bone cancer	0.000349	0.00514	CcSEcCtD
Propranolol—Bronchitis—Epirubicin—bone cancer	0.000349	0.00513	CcSEcCtD
Propranolol—Gastrointestinal disorder—Cisplatin—bone cancer	0.000347	0.0051	CcSEcCtD
Propranolol—Infestation—Methotrexate—bone cancer	0.000346	0.00508	CcSEcCtD
Propranolol—Infestation NOS—Methotrexate—bone cancer	0.000346	0.00508	CcSEcCtD
Propranolol—Depression—Methotrexate—bone cancer	0.000345	0.00507	CcSEcCtD
Propranolol—HTR1B—spinal cord—bone cancer	0.000344	0.0171	CbGeAlD
Propranolol—Pain—Cisplatin—bone cancer	0.000343	0.00505	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Methotrexate—bone cancer	0.000343	0.00504	CcSEcCtD
Propranolol—Neutropenia—Epirubicin—bone cancer	0.000339	0.00499	CcSEcCtD
Propranolol—Infestation NOS—Epirubicin—bone cancer	0.000323	0.00476	CcSEcCtD
Propranolol—Infestation—Epirubicin—bone cancer	0.000323	0.00476	CcSEcCtD
Propranolol—Bronchitis—Doxorubicin—bone cancer	0.000323	0.00475	CcSEcCtD
Propranolol—Agranulocytosis—Methotrexate—bone cancer	0.000322	0.00475	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Epirubicin—bone cancer	0.000321	0.00472	CcSEcCtD
Propranolol—Body temperature increased—Cisplatin—bone cancer	0.000317	0.00467	CcSEcCtD
Propranolol—Neutropenia—Doxorubicin—bone cancer	0.000314	0.00462	CcSEcCtD
Propranolol—Pharyngitis—Methotrexate—bone cancer	0.000308	0.00453	CcSEcCtD
Propranolol—Agranulocytosis—Epirubicin—bone cancer	0.000302	0.00444	CcSEcCtD
Propranolol—Infestation NOS—Doxorubicin—bone cancer	0.000299	0.0044	CcSEcCtD
Propranolol—Infestation—Doxorubicin—bone cancer	0.000299	0.0044	CcSEcCtD
Propranolol—Visual impairment—Methotrexate—bone cancer	0.000299	0.0044	CcSEcCtD
Propranolol—Stevens-Johnson syndrome—Doxorubicin—bone cancer	0.000297	0.00437	CcSEcCtD
Propranolol—Hypersensitivity—Cisplatin—bone cancer	0.000296	0.00435	CcSEcCtD
Propranolol—Bradycardia—Epirubicin—bone cancer	0.000296	0.00435	CcSEcCtD
Propranolol—Erythema multiforme—Methotrexate—bone cancer	0.000293	0.00432	CcSEcCtD
Propranolol—Asthenia—Cisplatin—bone cancer	0.000288	0.00424	CcSEcCtD
Propranolol—Pharyngitis—Epirubicin—bone cancer	0.000288	0.00424	CcSEcCtD
Propranolol—Cardiac disorder—Methotrexate—bone cancer	0.000288	0.00424	CcSEcCtD
Propranolol—Visual impairment—Epirubicin—bone cancer	0.00028	0.00412	CcSEcCtD
Propranolol—Agranulocytosis—Doxorubicin—bone cancer	0.000279	0.00411	CcSEcCtD
Propranolol—HTR1A—spinal cord—bone cancer	0.000277	0.0138	CbGeAlD
Propranolol—Diarrhoea—Cisplatin—bone cancer	0.000275	0.00404	CcSEcCtD
Propranolol—Erythema multiforme—Epirubicin—bone cancer	0.000274	0.00404	CcSEcCtD
Propranolol—Alopecia—Methotrexate—bone cancer	0.000274	0.00403	CcSEcCtD
Propranolol—Bradycardia—Doxorubicin—bone cancer	0.000273	0.00402	CcSEcCtD
Propranolol—Mental disorder—Methotrexate—bone cancer	0.000272	0.004	CcSEcCtD
Propranolol—Erythema—Methotrexate—bone cancer	0.00027	0.00397	CcSEcCtD
Propranolol—Cardiac disorder—Epirubicin—bone cancer	0.000269	0.00396	CcSEcCtD
Propranolol—Pharyngitis—Doxorubicin—bone cancer	0.000267	0.00392	CcSEcCtD
Propranolol—Visual impairment—Doxorubicin—bone cancer	0.000259	0.00381	CcSEcCtD
Propranolol—Alopecia—Epirubicin—bone cancer	0.000257	0.00377	CcSEcCtD
Propranolol—Vomiting—Cisplatin—bone cancer	0.000255	0.00376	CcSEcCtD
Propranolol—Mental disorder—Epirubicin—bone cancer	0.000254	0.00374	CcSEcCtD
Propranolol—Erythema multiforme—Doxorubicin—bone cancer	0.000254	0.00374	CcSEcCtD
Propranolol—Rash—Cisplatin—bone cancer	0.000253	0.00373	CcSEcCtD
Propranolol—Dermatitis—Cisplatin—bone cancer	0.000253	0.00372	CcSEcCtD
Propranolol—Erythema—Epirubicin—bone cancer	0.000253	0.00372	CcSEcCtD
Propranolol—Cardiac disorder—Doxorubicin—bone cancer	0.000249	0.00367	CcSEcCtD
Propranolol—Vertigo—Methotrexate—bone cancer	0.000243	0.00357	CcSEcCtD
Propranolol—Nausea—Cisplatin—bone cancer	0.000239	0.00351	CcSEcCtD
Propranolol—Alopecia—Doxorubicin—bone cancer	0.000237	0.00349	CcSEcCtD
Propranolol—Cough—Methotrexate—bone cancer	0.000236	0.00347	CcSEcCtD
Propranolol—Mental disorder—Doxorubicin—bone cancer	0.000235	0.00346	CcSEcCtD
Propranolol—Convulsion—Methotrexate—bone cancer	0.000234	0.00344	CcSEcCtD
Propranolol—Erythema—Doxorubicin—bone cancer	0.000234	0.00344	CcSEcCtD
Propranolol—Agitation—Epirubicin—bone cancer	0.000232	0.00342	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—bone cancer	0.000228	0.00336	CcSEcCtD
Propranolol—Vertigo—Epirubicin—bone cancer	0.000227	0.00334	CcSEcCtD
Propranolol—Cough—Epirubicin—bone cancer	0.000221	0.00324	CcSEcCtD
Propranolol—Anaphylactic shock—Methotrexate—bone cancer	0.00022	0.00324	CcSEcCtD
Propranolol—Convulsion—Epirubicin—bone cancer	0.000219	0.00322	CcSEcCtD
Propranolol—Infection—Methotrexate—bone cancer	0.000219	0.00322	CcSEcCtD
Propranolol—Nervous system disorder—Methotrexate—bone cancer	0.000216	0.00318	CcSEcCtD
Propranolol—Agitation—Doxorubicin—bone cancer	0.000215	0.00316	CcSEcCtD
Propranolol—Skin disorder—Methotrexate—bone cancer	0.000214	0.00315	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—bone cancer	0.000214	0.00314	CcSEcCtD
Propranolol—Vertigo—Doxorubicin—bone cancer	0.00021	0.00309	CcSEcCtD
Propranolol—Anaphylactic shock—Epirubicin—bone cancer	0.000206	0.00303	CcSEcCtD
Propranolol—Infection—Epirubicin—bone cancer	0.000205	0.00302	CcSEcCtD
Propranolol—Cough—Doxorubicin—bone cancer	0.000204	0.003	CcSEcCtD
Propranolol—Convulsion—Doxorubicin—bone cancer	0.000203	0.00298	CcSEcCtD
Propranolol—Nervous system disorder—Epirubicin—bone cancer	0.000202	0.00298	CcSEcCtD
Propranolol—Skin disorder—Epirubicin—bone cancer	0.0002	0.00295	CcSEcCtD
Propranolol—Insomnia—Methotrexate—bone cancer	0.000199	0.00293	CcSEcCtD
Propranolol—Paraesthesia—Methotrexate—bone cancer	0.000198	0.00291	CcSEcCtD
Propranolol—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—bone cancer	0.000198	0.00291	CcSEcCtD
Propranolol—Dyspnoea—Methotrexate—bone cancer	0.000196	0.00289	CcSEcCtD
Propranolol—Somnolence—Methotrexate—bone cancer	0.000196	0.00288	CcSEcCtD
Propranolol—Dyspepsia—Methotrexate—bone cancer	0.000194	0.00285	CcSEcCtD
Propranolol—Decreased appetite—Methotrexate—bone cancer	0.000192	0.00282	CcSEcCtD
Propranolol—Anaphylactic shock—Doxorubicin—bone cancer	0.000191	0.00281	CcSEcCtD
Propranolol—Gastrointestinal disorder—Methotrexate—bone cancer	0.00019	0.0028	CcSEcCtD
Propranolol—Fatigue—Methotrexate—bone cancer	0.00019	0.0028	CcSEcCtD
Propranolol—Infection—Doxorubicin—bone cancer	0.00019	0.00279	CcSEcCtD
Propranolol—Pain—Methotrexate—bone cancer	0.000188	0.00277	CcSEcCtD
Propranolol—Nervous system disorder—Doxorubicin—bone cancer	0.000187	0.00275	CcSEcCtD
Propranolol—Insomnia—Epirubicin—bone cancer	0.000187	0.00274	CcSEcCtD
Propranolol—Skin disorder—Doxorubicin—bone cancer	0.000185	0.00273	CcSEcCtD
Propranolol—Paraesthesia—Epirubicin—bone cancer	0.000185	0.00273	CcSEcCtD
Propranolol—Dyspnoea—Epirubicin—bone cancer	0.000184	0.00271	CcSEcCtD
Propranolol—Somnolence—Epirubicin—bone cancer	0.000183	0.0027	CcSEcCtD
Propranolol—Dyspepsia—Epirubicin—bone cancer	0.000182	0.00267	CcSEcCtD
Propranolol—Gastrointestinal pain—Methotrexate—bone cancer	0.00018	0.00265	CcSEcCtD
Propranolol—Decreased appetite—Epirubicin—bone cancer	0.000179	0.00264	CcSEcCtD
Propranolol—Gastrointestinal disorder—Epirubicin—bone cancer	0.000178	0.00262	CcSEcCtD
Propranolol—Fatigue—Epirubicin—bone cancer	0.000178	0.00262	CcSEcCtD
Propranolol—Pain—Epirubicin—bone cancer	0.000176	0.0026	CcSEcCtD
Propranolol—Constipation—Epirubicin—bone cancer	0.000176	0.0026	CcSEcCtD
Propranolol—Urticaria—Methotrexate—bone cancer	0.000175	0.00258	CcSEcCtD
Propranolol—Abdominal pain—Methotrexate—bone cancer	0.000174	0.00256	CcSEcCtD
Propranolol—Body temperature increased—Methotrexate—bone cancer	0.000174	0.00256	CcSEcCtD
Propranolol—Insomnia—Doxorubicin—bone cancer	0.000173	0.00254	CcSEcCtD
Propranolol—Paraesthesia—Doxorubicin—bone cancer	0.000171	0.00252	CcSEcCtD
Propranolol—Dyspnoea—Doxorubicin—bone cancer	0.00017	0.0025	CcSEcCtD
Propranolol—Somnolence—Doxorubicin—bone cancer	0.00017	0.0025	CcSEcCtD
Propranolol—Gastrointestinal pain—Epirubicin—bone cancer	0.000169	0.00248	CcSEcCtD
Propranolol—Dyspepsia—Doxorubicin—bone cancer	0.000168	0.00247	CcSEcCtD
Propranolol—Decreased appetite—Doxorubicin—bone cancer	0.000166	0.00244	CcSEcCtD
Propranolol—Gastrointestinal disorder—Doxorubicin—bone cancer	0.000165	0.00242	CcSEcCtD
Propranolol—Fatigue—Doxorubicin—bone cancer	0.000165	0.00242	CcSEcCtD
Propranolol—Urticaria—Epirubicin—bone cancer	0.000164	0.00241	CcSEcCtD
Propranolol—Pain—Doxorubicin—bone cancer	0.000163	0.0024	CcSEcCtD
Propranolol—Constipation—Doxorubicin—bone cancer	0.000163	0.0024	CcSEcCtD
Propranolol—Body temperature increased—Epirubicin—bone cancer	0.000163	0.0024	CcSEcCtD
Propranolol—Abdominal pain—Epirubicin—bone cancer	0.000163	0.0024	CcSEcCtD
Propranolol—Hypersensitivity—Methotrexate—bone cancer	0.000162	0.00239	CcSEcCtD
Propranolol—Asthenia—Methotrexate—bone cancer	0.000158	0.00233	CcSEcCtD
Propranolol—Gastrointestinal pain—Doxorubicin—bone cancer	0.000156	0.0023	CcSEcCtD
Propranolol—Hypersensitivity—Epirubicin—bone cancer	0.000152	0.00224	CcSEcCtD
Propranolol—Urticaria—Doxorubicin—bone cancer	0.000152	0.00223	CcSEcCtD
Propranolol—Body temperature increased—Doxorubicin—bone cancer	0.000151	0.00222	CcSEcCtD
Propranolol—Abdominal pain—Doxorubicin—bone cancer	0.000151	0.00222	CcSEcCtD
Propranolol—Diarrhoea—Methotrexate—bone cancer	0.000151	0.00222	CcSEcCtD
Propranolol—Asthenia—Epirubicin—bone cancer	0.000148	0.00218	CcSEcCtD
Propranolol—Dizziness—Methotrexate—bone cancer	0.000146	0.00214	CcSEcCtD
Propranolol—Diarrhoea—Epirubicin—bone cancer	0.000141	0.00208	CcSEcCtD
Propranolol—Hypersensitivity—Doxorubicin—bone cancer	0.000141	0.00207	CcSEcCtD
Propranolol—Vomiting—Methotrexate—bone cancer	0.00014	0.00206	CcSEcCtD
Propranolol—Rash—Methotrexate—bone cancer	0.000139	0.00204	CcSEcCtD
Propranolol—Dermatitis—Methotrexate—bone cancer	0.000139	0.00204	CcSEcCtD
Propranolol—Asthenia—Doxorubicin—bone cancer	0.000137	0.00201	CcSEcCtD
Propranolol—Dizziness—Epirubicin—bone cancer	0.000136	0.00201	CcSEcCtD
Propranolol—Vomiting—Epirubicin—bone cancer	0.000131	0.00193	CcSEcCtD
Propranolol—Nausea—Methotrexate—bone cancer	0.000131	0.00193	CcSEcCtD
Propranolol—Diarrhoea—Doxorubicin—bone cancer	0.000131	0.00192	CcSEcCtD
Propranolol—Rash—Epirubicin—bone cancer	0.00013	0.00191	CcSEcCtD
Propranolol—Dermatitis—Epirubicin—bone cancer	0.00013	0.00191	CcSEcCtD
Propranolol—Dizziness—Doxorubicin—bone cancer	0.000126	0.00186	CcSEcCtD
Propranolol—Nausea—Epirubicin—bone cancer	0.000122	0.0018	CcSEcCtD
Propranolol—Vomiting—Doxorubicin—bone cancer	0.000121	0.00179	CcSEcCtD
Propranolol—Rash—Doxorubicin—bone cancer	0.00012	0.00177	CcSEcCtD
Propranolol—Dermatitis—Doxorubicin—bone cancer	0.00012	0.00177	CcSEcCtD
Propranolol—CYP3A5—Metapathway biotransformation—GSTP1—bone cancer	0.00012	0.00157	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—bone cancer	0.000119	0.00156	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—GRM1—bone cancer	0.000118	0.00155	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—NDUFA12—bone cancer	0.000118	0.00154	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—NDUFA12—bone cancer	0.000118	0.00154	CbGpPWpGaD
Propranolol—ADRB1—GPCR ligand binding—SMO—bone cancer	0.000117	0.00153	CbGpPWpGaD
Propranolol—CYP1A1—Biological oxidations—GSTP1—bone cancer	0.000115	0.0015	CbGpPWpGaD
Propranolol—ADRB2—GPCR ligand binding—SMO—bone cancer	0.000115	0.0015	CbGpPWpGaD
Propranolol—Nausea—Doxorubicin—bone cancer	0.000113	0.00167	CcSEcCtD
Propranolol—CYP1A1—Metapathway biotransformation—GSTP1—bone cancer	0.000113	0.00148	CbGpPWpGaD
Propranolol—CYP1A2—Tryptophan metabolism—MDM2—bone cancer	0.000113	0.00148	CbGpPWpGaD
Propranolol—HTR1A—GPCR ligand binding—SMO—bone cancer	0.000112	0.00147	CbGpPWpGaD
Propranolol—CYP2C19—Biological oxidations—CYP3A4—bone cancer	0.00011	0.00144	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—bone cancer	0.000109	0.00142	CbGpPWpGaD
Propranolol—ABCB1—bone marrow—bone cancer	0.000109	0.00541	CbGeAlD
Propranolol—ADRB1—GPCR downstream signaling—RGS1—bone cancer	0.000109	0.00142	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—GRM4—bone cancer	0.000109	0.00142	CbGpPWpGaD
Propranolol—CYP2C19—Metapathway biotransformation—CYP3A4—bone cancer	0.000108	0.00142	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—bone cancer	0.000108	0.00142	CbGpPWpGaD
Propranolol—ABCB1—spinal cord—bone cancer	0.000108	0.00538	CbGeAlD
Propranolol—HTR1B—Signaling by GPCR—GRM1—bone cancer	0.000107	0.0014	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—RGS1—bone cancer	0.000106	0.00139	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—GRM4—bone cancer	0.000106	0.00139	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—RGS1—bone cancer	0.000104	0.00136	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—GRM4—bone cancer	0.000104	0.00136	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—GNA11—bone cancer	0.000102	0.00134	CbGpPWpGaD
Propranolol—CYP1A2—Arachidonic acid metabolism—PTGS2—bone cancer	0.000102	0.00133	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—SMO—bone cancer	0.000101	0.00133	CbGpPWpGaD
Propranolol—CYP2D6—Biological oxidations—CYP3A4—bone cancer	0.000101	0.00132	CbGpPWpGaD
Propranolol—CYP2D6—Metapathway biotransformation—CYP3A4—bone cancer	9.97e-05	0.0013	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—IL3—bone cancer	9.86e-05	0.00129	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—GRM4—bone cancer	9.86e-05	0.00129	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—RGS1—bone cancer	9.86e-05	0.00129	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—JUN—bone cancer	9.83e-05	0.00128	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—GRM4—bone cancer	9.81e-05	0.00128	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—RGS1—bone cancer	9.81e-05	0.00128	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—NT5C3A—bone cancer	9.77e-05	0.00128	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—NT5C3A—bone cancer	9.75e-05	0.00127	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—CHEK2—bone cancer	9.73e-05	0.00127	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—RGS1—bone cancer	9.65e-05	0.00126	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—GRM4—bone cancer	9.65e-05	0.00126	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—BRAF—bone cancer	9.55e-05	0.00125	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—GRM4—bone cancer	9.43e-05	0.00123	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—RGS1—bone cancer	9.43e-05	0.00123	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—GRM1—bone cancer	9.42e-05	0.00123	CbGpPWpGaD
Propranolol—CYP2C19—Biological oxidations—GSTP1—bone cancer	9.4e-05	0.00123	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—GNA11—bone cancer	9.28e-05	0.00121	CbGpPWpGaD
Propranolol—CYP2C19—Metapathway biotransformation—GSTP1—bone cancer	9.27e-05	0.00121	CbGpPWpGaD
Propranolol—ADRB3—GPCR downstream signaling—IL3—bone cancer	9.27e-05	0.00121	CbGpPWpGaD
Propranolol—ABCB1—HIF-1-alpha transcription factor network—JUN—bone cancer	9.22e-05	0.00121	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—GRM1—bone cancer	9.21e-05	0.0012	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—GRM1—bone cancer	9.01e-05	0.00118	CbGpPWpGaD
Propranolol—CYP3A4—Tryptophan metabolism—MDM2—bone cancer	8.72e-05	0.00114	CbGpPWpGaD
Propranolol—CYP2D6—Biological oxidations—GSTP1—bone cancer	8.65e-05	0.00113	CbGpPWpGaD
Propranolol—CYP1A2—Biological oxidations—CYP3A4—bone cancer	8.56e-05	0.00112	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—GRM1—bone cancer	8.55e-05	0.00112	CbGpPWpGaD
Propranolol—CYP2D6—Metapathway biotransformation—GSTP1—bone cancer	8.53e-05	0.00111	CbGpPWpGaD
Propranolol—HTR1A—SIDS Susceptibility Pathways—JUN—bone cancer	8.53e-05	0.00111	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—NDUFA12—bone cancer	8.52e-05	0.00111	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—GRM1—bone cancer	8.51e-05	0.00111	CbGpPWpGaD
Propranolol—CYP1A2—Metapathway biotransformation—CYP3A4—bone cancer	8.45e-05	0.0011	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—IL3—bone cancer	8.42e-05	0.0011	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—GRM1—bone cancer	8.36e-05	0.00109	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—BRCA2—bone cancer	8.25e-05	0.00108	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—TUBB4B—bone cancer	8.22e-05	0.00108	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—GRM1—bone cancer	8.18e-05	0.00107	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NDUFA12—bone cancer	8.05e-05	0.00105	CbGpPWpGaD
Propranolol—SLC22A2—Transmission across Chemical Synapses—MDM2—bone cancer	8e-05	0.00105	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—bone cancer	7.73e-05	0.00101	CbGpPWpGaD
Propranolol—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—bone cancer	7.73e-05	0.00101	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—GNA11—bone cancer	7.62e-05	0.000996	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—SMO—bone cancer	7.56e-05	0.000989	CbGpPWpGaD
Propranolol—CYP1A2—Biological oxidations—GSTP1—bone cancer	7.32e-05	0.000957	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—BRAF—bone cancer	7.31e-05	0.000956	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—RGS1—bone cancer	7.31e-05	0.000956	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—GRM4—bone cancer	7.31e-05	0.000956	CbGpPWpGaD
Propranolol—CYP1A2—Metapathway biotransformation—GSTP1—bone cancer	7.22e-05	0.000944	CbGpPWpGaD
Propranolol—ABCB1—Transmembrane transport of small molecules—TUBB2A—bone cancer	7.1e-05	0.000928	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—NT5C3A—bone cancer	7.06e-05	0.000923	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—GNA11—bone cancer	6.92e-05	0.000904	CbGpPWpGaD
Propranolol—HTR1B—GPCR downstream signaling—IL3—bone cancer	6.91e-05	0.000903	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—NT5C3A—bone cancer	6.67e-05	0.000872	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NDUFA12—bone cancer	6.59e-05	0.000861	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NDUFA12—bone cancer	6.43e-05	0.000841	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—GRM1—bone cancer	6.34e-05	0.000829	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—IL3—bone cancer	6.27e-05	0.00082	CbGpPWpGaD
Propranolol—SLC22A2—Neuronal System—MDM2—bone cancer	6.13e-05	0.000801	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—bone cancer	6.12e-05	0.000799	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—GNA11—bone cancer	6.07e-05	0.000793	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NDUFA12—bone cancer	6.06e-05	0.000792	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—SMO—bone cancer	6.02e-05	0.000787	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—SMO—bone cancer	6e-05	0.000784	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—GNA11—bone cancer	5.93e-05	0.000776	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—SMO—bone cancer	5.89e-05	0.00077	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—GRM4—bone cancer	5.83e-05	0.000761	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—RGS1—bone cancer	5.83e-05	0.000761	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—GNA11—bone cancer	5.8e-05	0.000759	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—SMO—bone cancer	5.76e-05	0.000753	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—RGS1—bone cancer	5.7e-05	0.000745	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—GRM4—bone cancer	5.7e-05	0.000745	CbGpPWpGaD
Propranolol—CYP3A4—Biological oxidations—GSTP1—bone cancer	5.65e-05	0.000739	CbGpPWpGaD
Propranolol—CYP3A4—Metapathway biotransformation—GSTP1—bone cancer	5.57e-05	0.000729	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—GRM4—bone cancer	5.57e-05	0.000728	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—RGS1—bone cancer	5.57e-05	0.000728	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—GNA11—bone cancer	5.51e-05	0.00072	CbGpPWpGaD
Propranolol—ADRB1—GPCR downstream signaling—IL3—bone cancer	5.5e-05	0.000719	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—GNA11—bone cancer	5.48e-05	0.000717	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—NT5C3A—bone cancer	5.46e-05	0.000714	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—GNA11—bone cancer	5.39e-05	0.000705	CbGpPWpGaD
Propranolol—ADRB2—GPCR downstream signaling—IL3—bone cancer	5.38e-05	0.000703	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—NT5C3A—bone cancer	5.33e-05	0.000696	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—GNA11—bone cancer	5.27e-05	0.000689	CbGpPWpGaD
Propranolol—HTR1A—GPCR downstream signaling—IL3—bone cancer	5.26e-05	0.000688	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NDUFA12—bone cancer	5.13e-05	0.000671	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—ATF1—bone cancer	5.1e-05	0.000666	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—GRM1—bone cancer	5.05e-05	0.00066	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—NT5C3A—bone cancer	5.02e-05	0.000656	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—IL3—bone cancer	4.99e-05	0.000653	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IL3—bone cancer	4.97e-05	0.00065	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—GRM1—bone cancer	4.94e-05	0.000646	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—IL3—bone cancer	4.89e-05	0.000639	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—GRM1—bone cancer	4.83e-05	0.000632	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—IL3—bone cancer	4.78e-05	0.000625	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—MDM2—bone cancer	4.53e-05	0.000593	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—SMO—bone cancer	4.47e-05	0.000584	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—bone cancer	4.37e-05	0.000571	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—ENO2—bone cancer	4.28e-05	0.000559	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—ENO2—bone cancer	4.27e-05	0.000558	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—NT5C3A—bone cancer	4.25e-05	0.000556	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TGFBR2—bone cancer	4.25e-05	0.000556	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—GNA11—bone cancer	4.09e-05	0.000534	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—IGF1R—bone cancer	4e-05	0.000523	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—DHFR—bone cancer	3.97e-05	0.000519	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—DHFR—bone cancer	3.96e-05	0.000518	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NDUFA12—bone cancer	3.96e-05	0.000518	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—bone cancer	3.94e-05	0.000515	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—ATF1—bone cancer	3.8e-05	0.000497	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—GNA11—bone cancer	3.71e-05	0.000485	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IL3—bone cancer	3.7e-05	0.000484	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—GNA11—bone cancer	3.7e-05	0.000484	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—SMO—bone cancer	3.56e-05	0.000465	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—SMO—bone cancer	3.48e-05	0.000455	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—SMO—bone cancer	3.4e-05	0.000445	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—CYP3A4—bone cancer	3.36e-05	0.00044	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—CYP3A4—bone cancer	3.36e-05	0.000439	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—NT5C3A—bone cancer	3.28e-05	0.000429	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—GNA11—bone cancer	3.25e-05	0.000425	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—GNA11—bone cancer	3.18e-05	0.000416	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TGFBR2—bone cancer	3.17e-05	0.000414	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—GNA11—bone cancer	3.11e-05	0.000407	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—bone cancer	3.1e-05	0.000405	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—ENO2—bone cancer	3.09e-05	0.000404	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—ATF1—bone cancer	3.03e-05	0.000396	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—IGF1R—bone cancer	2.98e-05	0.00039	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—ATF1—bone cancer	2.96e-05	0.000387	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IL3—bone cancer	2.95e-05	0.000386	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—ENO2—bone cancer	2.92e-05	0.000382	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—KIT—bone cancer	2.9e-05	0.000379	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—ATF1—bone cancer	2.89e-05	0.000378	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IL3—bone cancer	2.89e-05	0.000377	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—GSTP1—bone cancer	2.88e-05	0.000376	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—GSTP1—bone cancer	2.87e-05	0.000375	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—DHFR—bone cancer	2.87e-05	0.000375	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IL3—bone cancer	2.82e-05	0.000369	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—BRAF—bone cancer	2.73e-05	0.000356	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—DHFR—bone cancer	2.71e-05	0.000354	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GNA11—bone cancer	2.68e-05	0.000351	CbGpPWpGaD
Propranolol—ADRB3—Signaling by GPCR—EGFR—bone cancer	2.64e-05	0.000346	CbGpPWpGaD
Propranolol—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—bone cancer	2.6e-05	0.00034	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GNA11—bone cancer	2.53e-05	0.000331	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TGFBR2—bone cancer	2.52e-05	0.00033	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TGFBR2—bone cancer	2.47e-05	0.000323	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—CYP3A4—bone cancer	2.43e-05	0.000318	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TGFBR2—bone cancer	2.41e-05	0.000316	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—ENO2—bone cancer	2.39e-05	0.000313	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—IGF1R—bone cancer	2.37e-05	0.00031	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—ENO2—bone cancer	2.33e-05	0.000305	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—IGF1R—bone cancer	2.32e-05	0.000304	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—CYP3A4—bone cancer	2.3e-05	0.0003	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	2.29e-05	0.000299	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MDM2—bone cancer	2.28e-05	0.000299	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—IGF1R—bone cancer	2.27e-05	0.000297	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—DHFR—bone cancer	2.22e-05	0.00029	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—ENO2—bone cancer	2.2e-05	0.000287	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—DHFR—bone cancer	2.17e-05	0.000283	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—KIT—bone cancer	2.16e-05	0.000283	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—GSTP1—bone cancer	2.08e-05	0.000272	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GNA11—bone cancer	2.07e-05	0.000271	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—DHFR—bone cancer	2.04e-05	0.000267	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—BRAF—bone cancer	2.03e-05	0.000266	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GNA11—bone cancer	2.02e-05	0.000265	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—JUN—bone cancer	1.99e-05	0.00026	CbGpPWpGaD
Propranolol—HTR1B—Signaling by GPCR—EGFR—bone cancer	1.97e-05	0.000258	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—GSTP1—bone cancer	1.96e-05	0.000257	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—MMP9—bone cancer	1.93e-05	0.000253	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GNA11—bone cancer	1.91e-05	0.000249	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—CYP3A4—bone cancer	1.88e-05	0.000246	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.87e-05	0.000244	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—ENO2—bone cancer	1.86e-05	0.000244	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—CYP3A4—bone cancer	1.83e-05	0.00024	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—CYP3A4—bone cancer	1.73e-05	0.000226	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—DHFR—bone cancer	1.73e-05	0.000226	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—KIT—bone cancer	1.72e-05	0.000225	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MDM2—bone cancer	1.7e-05	0.000223	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—KIT—bone cancer	1.68e-05	0.00022	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—KIT—bone cancer	1.65e-05	0.000215	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—BRAF—bone cancer	1.62e-05	0.000212	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GNA11—bone cancer	1.62e-05	0.000211	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—GSTP1—bone cancer	1.61e-05	0.00021	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—BRAF—bone cancer	1.58e-05	0.000207	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—GSTP1—bone cancer	1.57e-05	0.000205	CbGpPWpGaD
Propranolol—ADRB1—Signaling by GPCR—EGFR—bone cancer	1.57e-05	0.000205	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—EGFR—bone cancer	1.56e-05	0.000204	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—BRAF—bone cancer	1.55e-05	0.000202	CbGpPWpGaD
Propranolol—ADRB2—Signaling by GPCR—EGFR—bone cancer	1.53e-05	0.000201	CbGpPWpGaD
Propranolol—HTR1A—Signaling by GPCR—EGFR—bone cancer	1.5e-05	0.000196	CbGpPWpGaD
Propranolol—CYP3A7—Metabolism—PTGS2—bone cancer	1.49e-05	0.000195	CbGpPWpGaD
Propranolol—SLC22A2—Metabolism—PTGS2—bone cancer	1.49e-05	0.000194	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—JUN—bone cancer	1.48e-05	0.000193	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—GSTP1—bone cancer	1.48e-05	0.000193	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—CYP3A4—bone cancer	1.46e-05	0.000191	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—bone cancer	1.46e-05	0.00019	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—MMP9—bone cancer	1.44e-05	0.000188	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—ENO2—bone cancer	1.44e-05	0.000188	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MDM2—bone cancer	1.36e-05	0.000177	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—DHFR—bone cancer	1.33e-05	0.000174	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MDM2—bone cancer	1.33e-05	0.000173	CbGpPWpGaD
Propranolol—ADRB3—Signaling Pathways—TP53—bone cancer	1.31e-05	0.000171	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MDM2—bone cancer	1.3e-05	0.00017	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—GSTP1—bone cancer	1.25e-05	0.000164	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GNA11—bone cancer	1.25e-05	0.000163	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—JUN—bone cancer	1.18e-05	0.000154	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—EGFR—bone cancer	1.16e-05	0.000152	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—JUN—bone cancer	1.15e-05	0.000151	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—MMP9—bone cancer	1.15e-05	0.00015	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—JUN—bone cancer	1.13e-05	0.000147	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—MMP9—bone cancer	1.12e-05	0.000147	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—MMP9—bone cancer	1.1e-05	0.000143	CbGpPWpGaD
Propranolol—CYP3A5—Metabolism—PTGS2—bone cancer	1.08e-05	0.000141	CbGpPWpGaD
Propranolol—CYP1A1—Metabolism—PTGS2—bone cancer	1.02e-05	0.000133	CbGpPWpGaD
Propranolol—HTR1B—Signaling Pathways—TP53—bone cancer	9.77e-06	0.000128	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—GSTP1—bone cancer	9.67e-06	0.000126	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—EGFR—bone cancer	9.27e-06	0.000121	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—EGFR—bone cancer	9.07e-06	0.000119	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—EGFR—bone cancer	8.86e-06	0.000116	CbGpPWpGaD
Propranolol—CYP2C19—Metabolism—PTGS2—bone cancer	8.33e-06	0.000109	CbGpPWpGaD
Propranolol—ABCB1—Metabolism—PTGS2—bone cancer	8.13e-06	0.000106	CbGpPWpGaD
Propranolol—ADRB1—Signaling Pathways—TP53—bone cancer	7.78e-06	0.000102	CbGpPWpGaD
Propranolol—CYP2D6—Metabolism—PTGS2—bone cancer	7.66e-06	0.0001	CbGpPWpGaD
Propranolol—ADRB2—Signaling Pathways—TP53—bone cancer	7.61e-06	9.95e-05	CbGpPWpGaD
Propranolol—HTR1A—Signaling Pathways—TP53—bone cancer	7.44e-06	9.73e-05	CbGpPWpGaD
Propranolol—CYP1A2—Metabolism—PTGS2—bone cancer	6.49e-06	8.48e-05	CbGpPWpGaD
Propranolol—CYP3A4—Metabolism—PTGS2—bone cancer	5.01e-06	6.55e-05	CbGpPWpGaD
